Novel agents like SIRPa-Fc fusion proteins and GPC3-CD47 bispecific antibodies have demonstrated potential to convert “cold” HCC tumors into “hot” immune-responsive tumors, but their optimal integration with ICIs remains under investigation [128]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.